1American Diabetes Association. Clinical Practice Recommendations 2006. Diabetes Care. 2006;29:s43-s48.
2Festa A,WiUiams K,D'Agostino R,etal.The natural course of β-cell function in nondiabetic and diabetic individuals.The Insulin Resistance Atherosclerosis study.Diabetes.2006;55:l 114-1120.
3中华医学会内分泌学会.中华内分泌代谢杂志,2011,:371-374.
4Zimmet P,Alberti KG,Shaw J. Global and societal implications of the diabelesepidemic. Nature. 2001;414:782-787.
5Wei M,Gaskill SP,Haffner SM,Stern ME Effects of diabetes and level ofglycemia on all-cause and cardiovascular mortality,The San Anlonio Heart Study.Diabetes Care. 1998;21:1167 - 1172.
6Morrish NJ;Wang SL,Stevens LK,Fuller JH. Keen H. Mortality and causes of death in lhe WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S14-s21.
7The Diabetes Control and Complications Trial Research Group. The effect of ntensive treatment of diabetes on the development and progression Of long'term complications in insulin dependent diabetes mellitus. N Eng J Med. 1993;329:977-986.
8UK Prospective Diabetes Study (UKPDS)Group. Intensive blood-glucose control with sulphonylureas or insulin compared wilh conventionaI treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)Lancet. 1 998;352:837-853.
9UK Prospective Diabetes Study(UKPDS)Group. Effect of intensive blood-glucose control with mefformin on complications in ovenweight patients with type 2 diabetes (UKPDS 34), Lancet. 1998;352: 854-865.
10Drouin P and the Diamicron MR study group. Diamicron MR is effective and welltolerated once daily in type 2 diabetes:a double. blind, randomized, multlaaliOnalsludy. J Diabetes Complications. 2000;14:185-191.
